Inicio › Leucemia linfoblástica aguda › Illinois
Ensayos clínicos de Leucemia linfoblástica aguda en Illinois
20 estudios sobre Leucemia linfoblástica aguda buscan participantes en Illinois.
Ciudades en Illinois
Texto oficial del estudio (inglés)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- OSF Saint Anthony's Health Center, Alton
- Rush-Copley Medical Center, Aurora
- Advocate Outpatient Center - Aurora, Aurora
- y 54 más
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
Edades de 40 a 75 · Todos los sexos · Actualizado el 2 oct 2026 · NCT05334069A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- The University of Chicago Medical Center, Chicago
ReclutandoFase 1/2
30 Days · Todos los sexos · Actualizado el 16 sept 2026 · NCT04065399The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Lurie Children's Hospital-Chicago, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- y 6 más
ReclutandoFase 1/2
Hasta los 22 · Todos los sexos · Actualizado el 25 ago 2026 · NCT04726241Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
ReclutandoFase 2
Edades de 7 a 25 · Todos los sexos · Actualizado el 19 ago 2026 · NCT05082519A Study of CTD402 in T-ALL/LBL Patients
- University of Chicago, Chicago
ReclutandoFase 1/2
Edades de 1 en adelante · Todos los sexos · Actualizado el 19 ago 2026 · NCT07070219Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment
- The University of Chicago, Chicago
ReclutandoEstudio observacional
1 Day – 17 Years · Todos los sexos · Actualizado el 14 ago 2026 · NCT06274788Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
- Research Site, Decatur
ReclutandoFase 1/2
Edades de 16 en adelante · Todos los sexos · Actualizado el 20 jul 2026 · NCT07155226Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
- Research Site, Chicago
ReclutandoFase 1/2
Edades de 12 en adelante · Todos los sexos · Actualizado el 13 jul 2026 · NCT07109219Using Text Messages to Improve Oral Chemotherapy for Adolescents and Adults With Acute Lymphoblastic Leukemia
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
Reclutando
Edades de 15 en adelante · Todos los sexos · Actualizado el 10 jul 2026 · NCT06446661A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Northwestern Memorial Hospital, Chicago
- Rush University Medical Center, Chicago
- University of Illinois at Chicago, Chicago
- y 3 más
ReclutandoEstudio observacional
Todas las edades · Todos los sexos · Actualizado el 6 jul 2026 · NCT01351545Mobile Health Intervention to Support Oral Chemotherapy Adherence in Adolescents and Young Adults With Leukemia
- Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago
Reclutando
Edades de 14 en adelante · Todos los sexos · Actualizado el 30 jun 2026 · NCT03932903Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia
- University of Chicago Medical Center, Chicago
ReclutandoFase 1
Edades de 18 a 39 · Todos los sexos · Actualizado el 29 jun 2026 · NCT03571321Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)
- University of Chicago Medical Center, Chicago
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 5 jun 2026 · NCT04747912Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- Lurie Children's Hospital-Chicago, Chicago
- Advocate Children's Hospital-Oak Lawn, Oak Lawn
- Saint Jude Midwest Affiliate, Peoria
ReclutandoEstudio observacional
Todas las edades · Todos los sexos · Actualizado el 18 may 2026 · NCT01790152Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- University of Chicago, Chicago
ReclutandoFase 1
Edades de 13 en adelante · Todos los sexos · Actualizado el 5 may 2026 · NCT04771572A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Northwestern, Chicago
ReclutandoFase 1/2
Edades de 12 en adelante · Todos los sexos · Actualizado el 24 mar 2026 · NCT04988555A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 18 mar 2026 · NCT06207123Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- University of Chicago Comprehensive Cancer Center, Chicago
ReclutandoFase 2
Edades de 18 a 54 · Todos los sexos · Actualizado el 17 mar 2026 · NCT06918431Venetoclax Basket Trial for High Risk Hematologic Malignancies
- Ann & Robert H Lurie Children's Hospital of Chicago, Chicago
ReclutandoFase 1
Edades de 1 a 40 · Todos los sexos · Actualizado el 12 mar 2026 · NCT05292664Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
ReclutandoFase 1
Edades de 1 a 21 · Todos los sexos · Actualizado el 6 dic 2024 · NCT05476770De ClinicalTrials.gov, datos obtenidos el 5 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.